CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 27 enrolled
Drug / intervention
Harmine Hydrochloride Capsulesdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05526430
NCT05526430Phase 1Completed
CompareCT.gov

A Phase I Dose Escalation Study of Harmine in Healthy Subjects

James Murrough·interventional·Posted Sep 2, 2022·Updated Jan 16, 2025

In Brief

A Phase 1 clinical trial evaluating Harmine Hydrochloride Capsules for Diabetes Mellitus. Completed, enrolled 27 participants across 1 site.

Detailed Summary

The present study is a phase 1 dose escalation study of harmine in healthy volunteers. The primary goal of the trial is to determine the maximum tolerated dose of harmine.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus
CountriesUnited States
CollaboratorsNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Timeline

Phase 1CompletedFinished
2023202420252026
First PostedSep 2, 2022
Enrollment StartSep 13, 2022
Primary CompletionJun 23, 2023
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 3.8 years ago

Interventions

Harmine Hydrochloride Capsulesdrug

capsules taken orally